Literature DB >> 24046394

Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M.

Carolina Lemos1, Teresa Coelho, Miguel Alves-Ferreira, Ana Martins-da-Silva, Jorge Sequeiros, Denisa Mendonça, Alda Sousa.   

Abstract

BACKGROUND: Early-onset (≤40 years) and later-onset (≥50 years) cases of familial amyloid polyneuropathy (FAP) ATTRV30M are not different entities, often coexisting in the same family, and showing anticipation (earlier age-at-onset (AO) in younger generations, usually associated with more severe phenotype). Historically, anticipation has been ascribed to ascertainment biases. Our aim was to study anticipation in a very large number of FAP kindreds, removing possible biases, and gain further insight into parent-of-origin effects.
METHODS: We analysed 926 parent-offspring pairs (from the Unidade Clínica de Paramiloidose roster, collected in 70 years), both clinically observed and had well-established AO, correcting for intrafamilial correlations.
RESULTS: Women had a significantly higher AO, either for daughters (mean: 33.70, SD: 6.84) vs sons (29.43, 6.08); or mothers (39.57, 11.75) vs. fathers (35.62, 11.62). Also, 291 pairs showed marked anticipation (≥10 years); the transmitting parent was the mother in 203 pairs. Mother-son pairs showed larger anticipation (10.43, 9.34), while father-daughter pairs showed only a residual anticipation (1.23, 9.77). Gender of offspring and parents was highly significant (with no interaction). To remove possible biases, we repeated analyses: (1) excluding the proband; (2) removing pairs with simultaneous onset; and (3) excluding offspring born after 1960. Anticipation was found in all subsamples, with the same trend for a parent-of-origin effect. Noteworthy, parents with AO ≤40 years never had offspring with AO ≥50.
CONCLUSIONS: These findings confirm anticipation as a true biological phenomenon, also in FAP ATTRV30M. Acknowledgment of anticipation may have important clinical implications in genetic counselling of offspring and in follow-up of mutation carriers.

Entities:  

Keywords:  AMYLOID; AUTONOMIC; EPIDEMIOLOGY; GENETICS; NEUROEPIDEMIOLOGY

Mesh:

Year:  2013        PMID: 24046394     DOI: 10.1136/jnnp-2013-305383

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  20 in total

1.  Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis.

Authors:  Andrea Iorio; Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Luca Pradotto; Alessandro Mauro; Anna Mazzeo; Claudia Stancanelli; Federico Perfetto; Sabrina Frusconi; Filomena My; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

2.  Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis.

Authors:  Ana Martins da Silva; Sara Cavaco; Joana Fernandes; Raquel Samões; Cristina Alves; Márcio Cardoso; Jeffery W Kelly; Cecília Monteiro; Teresa Coelho
Journal:  J Neurol       Date:  2017-12-05       Impact factor: 4.849

3.  A Trans-acting Factor May Modify Age at Onset in Familial Amyloid Polyneuropathy ATTRV30M in Portugal.

Authors:  Miguel Alves-Ferreira; Teresa Coelho; Diana Santos; Jorge Sequeiros; Isabel Alonso; Alda Sousa; Carolina Lemos
Journal:  Mol Neurobiol       Date:  2017-05-19       Impact factor: 5.590

Review 4.  FAP neuropathy and emerging treatments.

Authors:  David Adams; Marie Théaudin; Cecile Cauquil; Vincent Algalarrondo; Michel Slama
Journal:  Curr Neurol Neurosci Rep       Date:  2014-03       Impact factor: 5.081

Review 5.  The genetics of cardiac amyloidosis.

Authors:  Scott Arno; Jennifer Cowger
Journal:  Heart Fail Rev       Date:  2021-09-13       Impact factor: 4.654

6.  Variants in RBP4 and AR genes modulate age at onset in familial amyloid polyneuropathy (FAP ATTRV30M).

Authors:  Diana Santos; Teresa Coelho; Miguel Alves-Ferreira; Jorge Sequeiros; Denisa Mendonça; Isabel Alonso; Carolina Lemos; Alda Sousa
Journal:  Eur J Hum Genet       Date:  2015-08-19       Impact factor: 4.246

Review 7.  Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy.

Authors:  Violaine Plante-Bordeneuve
Journal:  J Neurol       Date:  2014-06-03       Impact factor: 4.849

8.  Ala97Ser transthyretin amyloidosis-associated polyneuropathy, clinical and neurophysiological profiles in a Thai cohort.

Authors:  Nath Pasutharnchat; Chamaiporn Taychargumpoo; Yongkasem Vorasettakarnkij; Jakkrit Amornvit
Journal:  BMC Neurol       Date:  2021-05-22       Impact factor: 2.474

9.  Ophthalmological manifestations in hereditary transthyretin (ATTR V30M) carriers: a review of 513 cases.

Authors:  João Melo Beirão; Jorge Malheiro; Carolina Lemos; Idalina Beirão; Paulo Costa; Paulo Torres
Journal:  Amyloid       Date:  2015-06-22       Impact factor: 7.141

Review 10.  Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.

Authors:  Yesim Parman; David Adams; Laura Obici; Lucía Galán; Velina Guergueltcheva; Ole B Suhr; Teresa Coelho
Journal:  Curr Opin Neurol       Date:  2016-02       Impact factor: 5.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.